BG
SPTX

Bellevue Group’s Seaport Therapeutics SPTX Stock Holding History

Bellevue Group’s Portfolio SPTX Stock Details SPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9M Buy
+1,100,000
New +$19.4M 0.5% 44

Other funds holding SPTX

GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Bellevue Group's SPTX Position: Q2 2026 in Review

Bellevue Group opened a new position in Seaport Therapeutics (SPTX) in Q2 2026: 1,100,000 shares worth $23.9M. The stake represents 0.5% of the portfolio and ranks #44 among its holdings.

42 funds tracked by Wall St. Rank hold SPTX as of Q2 2026.

  • Bellevue Group held 1,100,000 shares of Seaport Therapeutics worth $23.9M as of Q2 2026.
  • Seaport Therapeutics was a new Bellevue Group position in Q2 2026.
  • Seaport Therapeutics made up 0.5% of Bellevue Group's portfolio in Q2 2026, its #44 holding.
  • 42 funds tracked by Wall St. Rank held Seaport Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.